Nkarta, Inc.
Nkarta, Inc. (NKTX): 4 pipeline candidates · ~24 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
23.8 months
D/E 0.30
Lead: Phase 1/Phase 2
4 candidates
N/A
0 buys · 2 sells (180d)
A transparent, data-derived signal for Nkarta, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$188.9M
Cash
$30.1M
Quarterly Burn
$28.2M
Runway
23.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| fludarabine | Phase 1/Phase 2 |
| nkx019 | Phase 1/Phase 2 |
| nkx070 | Preclinical |
| nkx101 | Phase 1/Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
121
Total value held
$96.5M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 10,805,129 | $22.8M |
| blackrock, inc. | 4,508,473 | $9.5M |
| vanguard capital management llc | 4,022,842 | $8.5M |
| samsara biocapital, llc | 3,507,666 | $7.4M |
| alyeska investment group, l.p. | 2,084,840 | $4.4M |
| two sigma investments, lp | 2,047,376 | $4.3M |
| citadel advisors llc | 1,805,094 | $3.8M |
| renaissance technologies llc | 1,732,372 | $3.7M |
| wasatch advisors lp | 1,577,847 | $3.3M |
| tang capital management llc | 1,480,823 | $3.1M |
Showing top 10 of 121 institutional holders of Nkarta, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Nkarta, Inc.'s pipeline?
Nkarta, Inc. (NKTX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Nkarta, Inc.'s lead drug candidate?
Nkarta, Inc.'s most advanced tracked candidate is fludarabine (Phase 1/Phase 2) for Systemic Sclerosis; Lupus Nephritis.
What is Nkarta, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Nkarta, Inc. has approximately 23.8 months of cash runway.
What is Nkarta, Inc.'s market capitalization?
Nkarta, Inc.'s market capitalization is approximately $188.9M.
Who is the CEO of Nkarta, Inc.?
Mr. Paul J. Hastings is the chief executive officer of Nkarta, Inc. (NKTX).
Get the full picture on Nkarta, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.